Recent advances on the antiatherogenic effects of HDL-derived proteins and mimetic peptides

Current Pharmaceutical Design

Volumn 15, Issue 27, 2009, Pages 3146-3166

  Petraki, Maria P ^a   Mantani, Polyxeni T ^a   Tselepis, Alexandros D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; APOLIPOPROTEIN M; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL ESTER TRANSFER PROTEIN; CLUSTERIN; DEXTRO AMINO ACID; ETC 216; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LIVER TRIACYLGLYCEROL LIPASE; PEPTIDOMIMETIC AGENT; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; PLACEBO; PRAVASTATIN; SCAVENGER RECEPTOR B; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; ALPHA HELIX; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REPERFUSION INJURY; REVIEW; SINGLE DRUG DOSE;

ANIMALS; APOLIPOPROTEINS; APOPTOSIS; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; BIOMIMETIC MATERIALS; BLOOD COAGULATION; CHOLESTEROL; DRUG DESIGN; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; LIPOPROTEINS, HDL; OXIDATIVE STRESS; PEPTIDES; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70449333618     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789057977     Document Type: Review

References (298)

1. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000; 86: 19L-22L.
2. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20(8): 1253-1268 (Pubitemid 39120790)
3. Hersberger M, von Eckardstein A. Low high density lipoprotein cholesterol - physiological background, clinical importance and drug treatment. Drugs 2003; 63: 1907-1945 (Pubitemid 37108401)
4. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23: 370-378
5. von Eckardstein A, Hersberger M, Rohrer L. Current understanding of the metabolism and biological actions of HDL. Curr Opin Clin Nutr Metabolic Care 2005; 8: 147-152 (Pubitemid 40289474)
6. Lewis GF. Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr Opin Cardiol 2006; 21: 345-352
7. Asztalos BF, de la Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, Rothblat GH. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res 2005; 46: 2246-2253
8. Yokoyama S. Assembly of high-density lipoprotein. Arterioscler Thromb Vasc Biol 2006; 26: 20-27
9. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003; 23: 712-719 (Pubitemid 36566157)
10. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004; 101: 9774-9779 (Pubitemid 38869312)
11. Barter PJ, Kastelein JJ. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 2006; 47: 492-499 (Pubitemid 43170835)
12. Link JJ, Rohatgi A, de Lemos JA. HDL cholesterol: physiology, pathophysiology, and management. Curr Probl Cardiol 2007; 32: 268-314. (Pubitemid 46669678)
13. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-1232 (Pubitemid 40962099)
14. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 1992; 33: 141-166
15. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 2006; 84: 276-294
16. Ajees AA, Anantharamaiah GM, Mishra VK, Hussain MM, Murthy S. Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA 2006; 103: 2126-2131
17. Davidson WS, Hazlett T, Mantulin WW, Jonas A. The role of apolipoprotein AI domains in lipid binding. Proc Natl Acad Sci USA 1996; 93: 13605-13610 (Pubitemid 26424166)
18. Saito H, Dhanasekaran P, Nguyen D, Holvoet P, Lund-Katz S, Phillips MC. Domain structure and lipid interaction in human apolipoproteins A-I and E: a general model. J Biol Chem 2003; 278: 23227-23232 (Pubitemid 36830135)
19. Silva RAG, Hilliard GM, Fang J, Macha S, Davidson WS. A three-dimensional molecular model of lipid-free apolipoprotein A-I determined by cross-linking/mass spectrometry and sequence tracking. Biochemistry 2005; 44: 2759-2769 (Pubitemid 40293652)
20. Lagerstedt JO, Budamagunta MS, Oda MN, Voss JC. Electron paramagnetic resonance spectroscopy of site-directed spin labels reveals the structural heterogeneity in the N-terminal domain of apoA-I in solution. J Biol Chem 2007; 282: 9143-9149
21. Segrest JP. Amphipathic helixes and plasma lipoproteins: thermodynamic and geometric considerations. Chem Phys Lipids 1977; 18: 7-22.
22. Wald JH, Coormaghtigh E, De Meutter J, Ruysschaert JM, Jonas A. Investigation of the lipid domains and apolipoprotein orientation in reconstituted high density lipoproteins by fluorescence and IR methods. J Biol Chem 1990; 265: 20044-20050 (Pubitemid 120013968)
23. Borhani DW, Rogers DP, Engler JA, Brouillette CG. Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc Natl Acad Sci USA 1997; 94: 12291-12296
24. Brouillette CG, Anantharamaiah GM, Engler JA, Borhani DW. Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim Biophys Acta 2001; 1531: 4-46.
25. Klon AE, Segrest JP, Harvey SC. Comparative models for human apolipoprotein A-I bound to lipid in discoidal high-density lipoprotein particles. Biochemistry 2002; 41: 10895-10905
26. Koppaka V, Silvestro L, Engler JA, Brouillette CG, Axelsen PH. The structure of human lipoprotein A-I. J Biol Chem 1999; 274: 14541-14544
27. Panagotopulos SE, Horace EM, Maiorano JN, Davidson WS. Apolipoprotein A-I adopts a belt-like orientation in reconstituted high density lipoproteins. J Biol Chem 2001; 276: 42965-42970 (Pubitemid 37370976)
28. Segrest JP, Jones MK, Klon AE, Sheldahl CJ, Hellinger M, De Loof H, et al. A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J Biol Chem 1999; 274: 31755-31758 (Pubitemid 129503755)
29. Li H, Lyles DS, Thomas MJ, Pan W, Sorci-Thomas MG. Structural determination of lipid-bound ApoA-I using fluorescence resonance energy transfer. J Biol Chem 2000; 275: 37048-37054 (Pubitemid 32002121)
30. Silva RAG, Hilliard GM, Li L, Segrest JP, Davidson WS. A mass spectrometric determination of the conformation of dimeric apolipoprotein A-I in discoidal high density lipoproteins. Biochemistry 2005; 44: 8600-8607 (Pubitemid 40840425)
31. Bhat S, Sorci-Thomas MG, Alexander ET, Samuel MP, Thomas MJ. Intermolecular contact between globular N-terminal fold and C-terminal domain of ApoA-I stabilizes its lipid-bound conformation. J Biol Chem 2005; 280: 33015-33025
32. Mishra VK, Palgunachari MN, Segrest JP, Anantharamaiah GM. Interactions of synthetic peptide analogs of the class a amphipathic helix with lipids. J Biol Chem 1994; 269: 7185-7191
33. Li H, Lyles DS, Pan W, Alexander E, Thomas MJ, Sorci-Thomas MG. ApoA-I structure on discs and spheres. J Biol Chem 2002; 277: 39093-39101
34. Sparks DL, Phillips MC, Lund-Katz S. The conformation of apolipoprotein A-I in discoidal and spherical recombinant high density lipoprotein particles. J Biol Chem 1992; 267: 25830-25838 (Pubitemid 23013986)
35. Jonas A, Wald JH, Toohill KL, Krul ES, Kezdy KE. Apolipoprotein A-I Structure and Lipid Properties in Homogeneous, Reconstituted Spherical and Discoidal High Density Lipoproteins. J Biol Chem 1990; 265: 22123-22129
36. Segrest JP, Garber DW, Brouillette CG, Harvey SC, Anantharamaiah GM. The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem 1994; 45: 303-369
37. Frank PG, Marcel YL. Apolipoprotein A-I: structure-function relationships. J Lipid Res 2000; 41: 853-872
38. Scott BR, McManus DC, Franklin V, Mackenzy AG, Neville T, Sparks DL, et al. The N-terminal globular domain and the first class A amphipathic helix of apolipoprotein A-I important for lecithin: cholesterol acyltransferase activation and the maturation of high density lipoprotein in vivo. J Biol Chem 2001; 276: 48716-48724 (Pubitemid 37370567)
39. Reardon CA, Kan HY, Cabana V, Blachowicz L, Lukens JR, Wu Q, et al. In vivo studies of HDL assembly and metabolism using adenovirus-mediated transfer of apoA-I mutants in apoA-Ideficient mice. Biochemistry 2001; 40: 13670-13680
40. McManus DC, Scott BR, Frank PG, Franklin V, JR S, Marcel YL. Distinct central amphipathic a- helices in apolipoprotein A-I contribute to the in vivo maturation of high density lipoprotein by either activating lecithin-cholesterol acyltransferase or binding lipids. J Biol Chem 2000; 275: 5043-5051
41. Cho KH, Durbin DM, Jonas A. Role of individual amino acids of apolipoprotein A-I in the activation of lecithin:cholesterol acyltransferase and in HDL rearrangements. J Lipid Res 2001; 42: 379-389 (Pubitemid 32270062)
42. Vedhachalam C, Liu L, Nickel M, Dhanasekaran P, Anantharamaiah GM, Lund-Katz S, et al. Influence of apoA-I structure on the ABCA1 mediated efflux of cellular lipids. J Biol Chem 2004; 279: 49931-49939 (Pubitemid 39577801)
43. Zhang YZ, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 2003; 108: 661-663 (Pubitemid 36999247)
44. Brewer HB Jr, Remaley AT, Neufeld EB, Basso F, Joyce C. Regulation of plasma highdensity lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1755-1760 (Pubitemid 39350289)
45. Favari E, Lee M, Calabresi L, Franceschini G, Zimetti F, Bernini F, et al. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding Cassette Transporter A1 e but not Scavenger Receptor Class B Type I-mediated lipid efflux to high density lipoprotein. J Biol Chem 2004; 279: 9930-9936 (Pubitemid 38372593)
46. Thuahnai ST, Lund-Katz S, Williams DL, Phillips MC. Scavenger receptor class B, type I-mediated uptake of various lipids into cells. Influence of the nature of the donor particle interaction with the receptor. J Biol Chem 2001; 276: 43801-43808 (Pubitemid 37383945)
47. Lorenzi I, von Eckardstein A, Radosavljevic S, Rohrer L. Lipidation of apolipoprotein A-I by ATP-binding cassette transporter (ABC) A1 generates an interaction partner for ABCG1 but not for scavenger receptor BI. Biochim Biophys Acta 2008; 1781: 306-313 (Pubitemid 351172126)
48. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized LDL: Steps 2 & 3. J Lipid Res 2000; 41: 1495-1508 (Pubitemid 30743599)
49. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41: 1481-1494 (Pubitemid 30743598)
50. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residures of apolipoproteins AI and AII. J Biol Chem 1998; 273: 6088-6095 (Pubitemid 28144688)
51. Park SH, Park JH, Kang JS, Kang YH. Involvement of transcription factors in plasma HDL protection against TNF-alpha-induced vascular cell adhesion molecule-1 expression. Int J Biochem Cell Biol 2003; 35: 168-182
52. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15: 1987-1994
53. Calabresi L, Franceschini G, Sirtori CR, De Palma A, Saresella M, Ferrante P, et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 1997; 238: 61-65 (Pubitemid 27453274)
54. Wadham C, Albanese N, Roberts J, Wang L, Bagley CJ, Gamble JR, et al. High-density lipoproteins neutralize C-reactive protein-proinflammatory activity. Circulation 2004; 109: 2116-2122 (Pubitemid 38620221)
55. Ferrante P, Taramelli D. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 1997; 238: 61-65 (Pubitemid 27453274)
56. Gomaraschi M, Basilico N, Sisto F, Taramelli D, Eligini S, Colli S, et al. High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. Biochim Biophys Acta 2005; 1736: 136-143 (Pubitemid 41262571)
57. Assanasen C, Mineo C, Seetharam D, Yuhanna IS, Marcel YL, Connelly MA, et al. Cholesterol binding, efflux, and a PDZ interacting domain of scavenger receptor-BI mediate HDL initiated signaling. J Clin Invest 2005; 115: 969-977 (Pubitemid 40489401)
58. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001; 7: 853-857 (Pubitemid 32691642)
59. Sumi M, Sata M, Miura S-i, Rye K-A, Toya N, Kanaoka Y, et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27: 813-818 (Pubitemid 46606711)
60. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105: 1399-1402 (Pubitemid 34263266)
61. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003; 107: 2944-2948 (Pubitemid 36736637)
62. Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of ApoA-I. J Clin Invest 1988; 82: 803-807 (Pubitemid 18228332)
63. Lerch PG, Spycher MO, Doran JE. Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb Haemost 1998; 80: 316-320
64. Pomerantz KB, Fleisher LN, Tall AR, Cannon PJ. Enrichment of endothelial cell arachidonate by lipid transfer from high density lipoproteins: relationship to prostaglandin I2 synthesis. J Lipid Res 1985; 26: 1269-1276
65. Carlson LA. Effect of a single infusion of recombinant human proapolipoproteinA-I liposomes (synthetic HDL) on plasma lipoproteins in patients with low high density lipoprotein cholesterol. Nutr Metab Cardiovasc Dis 1995; 5: 85-91.
66. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999; 100: 594-598
67. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007; 297: 1675-1682 (Pubitemid 46631626)
68. Gualandri V, Franceschini G, Sirtori SR. Identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985; 37: 1083-1097 (Pubitemid 16145258)
69. Roma P, Gregg RE, Meng MS, Ronan R, Zech LA, Franceschini G, et al. In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia. J Clin Invest 1993; 91: 1445-1452
70. Franceschini G, Vecchio G, Gianfranceschi G, Magani D, Sirtori CR. Apolipoprotein A-Imilano.Accelerated binding and dissociation from lipids of a human apolipoprotein variant. J Biol Chem 1985; 260: 16321-16325 (Pubitemid 16172349)
71. Calabresi L, Vecchio G, Longhi R, Gianazza E, Palm G, Wadensten H, et al. Molecular characterization of native and recombinant apolipoprotein AIMilano dimer. The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein A-I. J Biol Chem 1994; 269: 32168-74.
72. Calabresi L, Vecchio G, Frigerio F, Vavassori L, Sirtori CR, Franceschini G. Reconstituted high-density lipoproteins with a disulfide-linked apolipoprotein A-I dimer: evidence for restricted particle size heterogeneity. Biochemistry 1997; 36: 12428-12433 (Pubitemid 27446665)
73. Franceschini G, Calabresi L, Chiesa G, Parolini C, Sirtori CR, Canavesi M, et al. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 1999; 19: 1257-1262 (Pubitemid 29227645)
74. Calabresi L, Canavesi M, Bernini F, Franceschini G. Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer. Biochemistry 1999; 38: 16307-16314 (Pubitemid 129520553)
75. Li D, Weng S, Yang B, Zander DS, Saldeen T, Nichols WW, et al. Inhibition of arterial thrombus formation by ApoA-I Milano. Arterioscler Thromb Vasc Biol 1999; 19: 378-383 (Pubitemid 29072754)
76. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-2300 (Pubitemid 37430562)
77. Parolini C, Marchesi M, Lorenzon P, Castano M, Balconi E, Miragoli L, et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-IMilano/1-palmitoyl-2-oleoyl phosphatidylcholine complex) administrations on rabbit lipid-rich soft plaques: in vivo assessment by IVUS and MRI. J Am Coll Cardiol 2008; 51: 1098-1103
78. Marchesi M, Booth EA, Davis T, Bisgaier CL, Lucchesi BR. Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury. J Pharmacol Exp Ther 2004; 311: 1023-1031
79. Marchesi M, Booth EA, Rossoni G, García RA, Hill KR, Sirtori CR, et al. Apolipoprotein A-IMilano/POPC complex attenuates postischemic ventricular dysfunction in the isolated rabbit heart. Atherosclerosis 2008; 197: 572-578
80. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T, Kapadia S, et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 2006; 47: 992-997 (Pubitemid 43312761)
81. Bielicki JK, McCall MR, Stolzfus LJ, Ravandi A, Kuksis A, Rubin EM, et al. Evidence that apolipoprotein A-IMilano has reduced capacity, compared with wild-type apolipoprotein A-I, to recruit membrane cholesterol. Arterioscler Thromb Vasc Biol 1997; 17: 1637-1643 (Pubitemid 27423980)
82. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005; 25: 1325-1331
83. Anantharamaiah GM, Jones JL, Brouillette CG, Schmidt CF, Chung BH, Hughes TA, et al. Studies of synthetic peptide analogs of amphipathic helix I: Structure of peptide/DMPC complexes. J Biol Chem 1985; 260: 10248-10255
84. Anantharamaiah GM. Synthetic peptide analogs of apolipoproteins. Methods Enzymol 1986; 128: 627-647
85. Van Lenten BJ, Wagner AC, Jung Chun-Ling, Ruchala P, Waring AJ, Lehrer RI, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I J Lipid Res 2008; 49: 2302-2311
86. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, et al. Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004; 109: r120-r 5.
87. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary L, et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 2002; 106: 1127-1132 (Pubitemid 34970855)
88. Van Lenten BJ, Wagner AC, M Navab, Anantharamaiah GM, Hui EK, Nayak DP, et al. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 2004; 110: 3252-3258
89. Buga GM, Frank JS, Mottino GA, Hakhamian A, Narasimha A, Watson AD, et al. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor null mice fed a Western diet. J Lipid Res 2008; 49: 192-205.
90. Ou J, Wang J, Xu H, Ou Z, Sorci-Thomas MG, Jones DW, et al. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on western diet. Circ Res 2005; 97: 1190-1197 (Pubitemid 43755213)
91. Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, Frank JS, et al. D-4F and statins synergize to render HDL anti-inflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25: 1426-1432 (Pubitemid 40923363)
92. Bloedon L, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, et al. Safety, pharmacokinetics and pharmacodynamics of a single dose of oral apolipoprotein A-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008; 49: 1344-1352
93. Yancey PG, Bielicki JK, Johnson WJ, Lund-Katz S, Palgunachari MN, Anantharamaiah GM, et al. Efflux of cellular cholesterol and phospholipids to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry 1995; 34: 7955-7965
94. Gomaraschi M, Calabresi L, Rossoni G, Iametti S, Franchescini G, Stonik J, et al. Anti-inflammatory and cardioprotective activities of synthetic HDL containing apolipoprotein A-I mimetic peptides. JPET 2008; 324: 776-783 (Pubitemid 351185837)
95. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Frank JS, et al. Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circ Res 2005; 97: 524-532 (Pubitemid 41361742)
96. Gillard BK, Chen YS, Gaubatz JW, Massey JB, Pownall HJ. Plasma factors required for human apolipoprotein A-II dimerization. Biochemistry 2005; 44: 471-479
97. Broedl UC, Jin W, Fuki IV, Millar JS, Rader DJ. Endothelial lipase is less effective at influencing HDL metabolism in vivo in mice expressing apoA-II. J Lipid Res 2006; 47: 2191-2197
98. Rye K-A, Wee K, Curtiss LK, Bonnet DJ, Barter PJ. Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation. J Biol Chem 2003; 278: 22530-22536 (Pubitemid 36830308)
99. Lagrost L, Persegol L, Lallemant C, Gambert P. Influence of apolipoprotein composition of high density lipoprotein particles on cholesteryl ester transfer protein activity. Particles containing various proportions of apolipoproteins AI and AII. J Biol Chem 1994; 269: 3189-3197 (Pubitemid 24237628)
100. Pussinen PJ, Jauhiainen M, Enholm C. ApoA-I/A-II molar ratio in the HDL particle influences phospholipid transfer protein-mediated HDL interconversion. J Lipid Res 1997; 38: 12-21. (Pubitemid 27097070)
101. Durbin DM, Jonas A. The effect of apolipoprotein A-II on the structure and function of apolipoprotein A-I in a homogeneous reconstituted high density lipoprotein particle. J Biol Chem 1997; 272: 31333-31339 (Pubitemid 28013267)
102. Jahn CE, Osborne JC, Schaefer EJ, Brewer HB. In vitro activation of the enzymic activity of hepatic lipase by apoA-II. FEBS Lett 1981; 131: 366-368
103. Hime NJ, Barter PJ, Rye KA. Evidence that apolipoprotein A-I facilitates hepatic lipase mediate phospholipid hydrolysis in reconstituted HDL containing apolipoprotein A-II. Biochemistry 2001; 40: 5496-5505
104. Zhong S, Goldberg IJ, Bruce C, Rubin E, Breslow JL, Tall A. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. J Clin Invest 1994; 94: 2457-2467 (Pubitemid 24379622)
105. de Beer MC, Durbin DM, Cai L, Mirocha N, Jonas A, Webb NR, et al. Apolipoprotein A-II modulates the binding and selective lipid uptake of reconstituted high density lipoprotein by scavenger receptor BI. J Biol Chem 2001; 276: 15832-15839 (Pubitemid 37391613)
106. Mehrabian M, Qiao JH, Hyman R, Ruddle D, Laughton C, Lusis AJ. Influence of the apoA-II gene locus on HDL levels and fatty streak development in mice. Arterioscler Thromb Vasc Biol 1993; 13: 1-10. (Pubitemid 23021577)
107. Bu X, Warden CH, Xia YR, De Meester C, Puppione DL, Teruya S, et al. Linkage analysis of the genetic determinants of high density lipoprotein concentrations and composition: evidence for involvement of the apolipoprotein A-II and cholesteryl ester transfer protein loci. Hum Genet 1994; 93: 639-648 (Pubitemid 24166489)
108. Allayee H, Castellani LW, Cantor RM, de Bruin TW, Lusis AJ. Biochemical and genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia. Circ Res 2003; 92: 1262-1267 (Pubitemid 36723655)
109. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993; 365: 762-764 (Pubitemid 23339884)
110. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 1993; 261: 469-472 (Pubitemid 23276555)
111. Ribas V, Sánchez-Quesada JL, Antón R, Camacho M, Julve J, Escolà-Gil JC, et al. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties. Circ Res 2004; 95: 789-797
112. Weinberg RB. Differences in the hydrophobic properties of discrete R-helical domains of rat and human apolipoprotein A-IV. Biochim Biophys Acta 1987; 918: 299-303.
113. Green PH, Glickman RM, Riley JW, Quinet E. Human apolipoprotein A-IV. Intestinal origin and distribution in plasma. J Clin Invest 1980; 65: 911-919 (Pubitemid 10144067)
114. Hayashi H, Nutting DF, Fujimoto K, Cardelli JA, Black D, Tso P. Transport of lipid and apolipoproteins A-I and A-IV in intestinal lymph of the rat. J Lipid Res 1990; 31: 1613-1625 (Pubitemid 20321722)
115. Pearson K, Saito H, Woods SC, Lund-Katz S, Tso P, Phillips MC, et al. Structure of human apolipoprotein A-IV: A distinct domain architecture among exchangeable apolipoproteins with potential functional implications. Biochemistry 2004; 43: 10719-10729 (Pubitemid 39096714)
116. Pearson K, Tubb MR, Tanaka M, Zhang XQ, Tso P, Weinberg RB, et al. Specific sequences in the N and C termini of apolipoprotein A-IV modulate its conformation and lipid association. J Biol Chem 2005; 280: 38576-38582 (Pubitemid 43853758)
117. Tubb MR, Gangani D. Silva RA, Pearson KJ, Tso P, Liu M, Davidson WS. Modulation of apolipoprotein A-IV lipid binding by an interaction between the N and C termini. J Biol Chem 2007; 282: 28385-28394 (Pubitemid 47606038)
118. Steinmetz A, Barbaras R, Ghalim N, Clavey V, Fruchart JC, Ailhaud G. Human apolipoprotein A-IV binds to apolipoprotein AI/A-II receptor sites and promotes cholesterol efflux from adipose cells. J Biol Chem 1990; 265: 7859-7863 (Pubitemid 20158953)
119. Barter PJ, Rajaram OV, Chang LB, Rye KA, Gambert P, Lagrost L, et al. Isolation of a high-density-lipoprotein conversion factor from human plasma. A possible role of apolipoprotein A-IV as its activator. Biochem J 1988; 254: 179-184
120. Dvorin E, Gorder NL, Benson DM, Gotto AM Jr. Apolipoprotein A-IV. A determinant for binding and uptake of high density lipoproteins by rat hepatocytes. J Biol Chem 1986; 261: 15714-15718 (Pubitemid 17208809)
121. Savion N, Gamliel A, Tauber JP, Gospodarowicz D. Free apolipoproteins A-I and A-IV present in human plasma displace high-density lipoprotein on cultured bovine aortic endothelial cells. Eur J Biochem 1987; 164: 435-443 (Pubitemid 17066670)
122. Duverger N, Ghalim N, Ailhaud G, Steinmetz A, Fruchart JC, Castro G. Characterization of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid. Arterioscler Thromb Vasc Biol 1993 126-132 (Pubitemid 23021593)
123. Weinstock PH, Bisgaier CL, Hayek T, Aalto-Setala K, Sehayek E, Wu L, et al. Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice. J Lipid Res 1997; 38: 1782-1794 (Pubitemid 27411270)
124. Cohen RD, Castellani LW, Qiao JH, Van Lenten BJ, Lusis AJ, Reue K. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest 1997; 99: 1906-1916 (Pubitemid 27175938)
125. Duverger N, Tremp G, Caillaud JM, Emmanuel F, Castro G, Fruchart JC, et al. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 1996; 273: 966-968 (Pubitemid 26275175)
126. Ostos MA, Conconi M, Vergnes L, Baroukh N, Ribalta J, Girona J, et al. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 1023-1028 (Pubitemid 34168663)
127. Ezeh B, Haiman M, Alber HF, Kunz B, Paulweber B, Lingenhel A, et al. Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. J Lipid Res 2003; 44: 1523-1529 (Pubitemid 37279597)
128. Kronenberg F, Kuen E, Ritz E, Konig P, Kraatz G, Lhotta K, et al. Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. J Am Soc Nephrol 2002; 13: 461-469 (Pubitemid 34106289)
129. Warner MM, Jingxuan G, Yiming Z. The relationship between plasma apolipoprotein A-IV levels and coronary heart disease. Chin Med J 2001; 114(3): 275-279 (Pubitemid 33611215)
130. Wong WM, Hawe E, Li LK, Miller GJ, Nicaud V, Pennacchio LA, et al. Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ Res 2003; 92: 969-975 (Pubitemid 36588495)
131. Jansen S, Lopez-Miranda J, Salas J, Ordovas JM, Castro P, Marin C, et al. Effect of 347-serine mutation in apoprotein A-IV on plasma LDL cholesterol response to dietary fat. Arterioscler Thromb Vasc Biol 1997; 17: 1532-1538 (Pubitemid 27387774)
132. Jansen S, Lopez-Miranda J, Ordovas JM, Zambrana JL, Marin C, Ostos MA, et al. Effect of 360His mutation in apolipoprotein A-IV on plasma HDL-cholesterol response to dietary fat. J Lipid Res 1997; 38: 1995-2002. (Pubitemid 27468008)
133. Nagasawa M, Akasaka Y, Ide T, Hara T, Kobayashi N, Utsumi M, et al. Highly sensitive upregulation of apolipoprotein A-IV by peroxisome proliferator-activated receptor a (PPARa) agonist in human hepatoma cells. Biochem Pharmacol 2007; 74: 1738-1746 (Pubitemid 350088678)
134. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, et
135. van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 2001; 276: 44512-44520 (Pubitemid 37391225)
136. Alborn WE, Johnson MG, Prince MJ, Konrad RJ. Definitive N-terminal protein sequence and further characterization of the novel apolipoprotein A5 in human serum. Clin Chem 2006; 52: 514-517
137. Weinberg RB, Cook VR, Beckstead JA, Martin DDO, Gallagher JW, Shelness GS, et al. Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem 2003; 278: 34438-34444 (Pubitemid 37553290)
138. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 1991; 252: 1817-1822 (Pubitemid 21917100)
139. O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 2005; 51: 351-359 (Pubitemid 40175805)
140. Lookene A, Beckstead JA, Nilsson S, Olivecrona G, Ryan RO. Apolipoprotein A-V-heparin Interactions. J Biol Chem 2005; 280: 25383-25387
141. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005; 280: 21553-21560 (Pubitemid 40805722)
142. Grosskopf I, Baroukh N, Lee SJ, Kamari Y, Harats D, Rubin EM, et al. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceriderich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol 2005; 25: 2573-2579 (Pubitemid 43732281)
143. Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RAFM, et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 2004; 279: 27941-27947 (Pubitemid 38900062)
144. Qu S, Perdomo G, Su D, D'Souza FM, Shachter NS, Dong HH. Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice. J Lipid Res 2007 48: 1476-1487 (Pubitemid 47312010)
145. Lauer SJ, Walker D, Elshourbagy NA, Reardon CA, Levywilson B, Taylor JM. Two copies of the human apolipoprotein C-I gene are linked closely to the apolipoprotein E gene. J Biol Chem 1988; 263: 7277-7286 (Pubitemid 18155754)
146. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism - functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999; 19: 472-484
147. Windler EE, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res 1985; 26: 556-565
148. Kowal RC, Herz J, Weisgraber H, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoprotein E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem 1990; 265: 10771-10779 (Pubitemid 20212821)
149. Sehayek E, Eisenberg S. Mechanisms of inhibition of apolipoprotein C of apolipoprotein E-dependent cellular metabo-lism of human triglyceride- rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 1991; 266: 18259-18267 (Pubitemid 21908074)
150. Westerterp M, de Haan W, Berbée JFP, Havekes LM, Rensen PCN. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL. J Lipid Res 2006; 47: 1203-1211 (Pubitemid 43830712)
151. Westerterp M, Berbée JFP, Pires NMM, van Mierlo GJD, Kleemann R, Romijn JA, et al. Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice. Circulation 2007; 116: 2173-2181 (Pubitemid 350060355)
152. Gautier T, Masson D, Pais de Barros JP, Athias A, Gambert P, Aunis D, et al. Human apolipoprotein C-I accounts for the ability of plasma high density lipoprotein to inhibit the cholesteryl ester transfer protein activity. J Biol Chem 2000; 275: 37504-37509 (Pubitemid 32004858)
153. Soutar AK, Garner CW, Baker HN, Sparrow JT, Jackson RL, Gotto Jr AM, et al. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyl transferase. Biochemistry 1975; 14: 3057-3064
154. de Haan W, Out R, Berbée JFP, van der Hoogt CC, van Dijk KW, van Berkel TJC, et al. Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo. Biochem Biophys Res Commun 2008; 377: 1294-1298
155. Westerterp M, Berbeé JFP, Delsing DJM, Jong MC, Gijbels MJJ, Dahlmans VEH, et al. Apolipoprotein C-I binds free fatty acids and reduces their intracellular esterification. J Lipid Res 2007; 48: 1353-1361 (Pubitemid 47312037)
156. Kolmakova A, Kwiterovich P, Virgil D, Alaupovic P, Knight-Gibson C, Martin SF, et al. Apolipoprotein C-I induces apoptosis in human aortic smooth muscle cells via recruiting neutral sphingomyelinase. Arterioscler Thromb Vasc Biol 2004; 24: 264-269 (Pubitemid 38202189)
157. Kushwaha RS, McGill Jr HC, Hausheer FH. Effect of synthetic truncated apolipoprotein C-I peptide on plasma lipoprotein cholesterol in nonhuman primates. J Biomed Biotechnol 2004; 4: 177-184
158. LaRosa JC, Levy RI, Herbert P, Lux SE, Fredrickson DS. A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun 1970; 41: 57-62.
159. Breckenridge WC, Little JA, Steiner G, Chow A, Poapst M. Hypertriglyceridemia associated with deficiency of apolipoprotein CII. N Engl J Med 1978; 298: 1265-1273 (Pubitemid 8361449)
160. Fojo SS, Law SW, Jr Brewer HB. Human apolipoprotein C-II: complete nucleic acid sequence of preapolipoprotein C-II. Proc Natl Acad Sci USA 1984; 81: 6354-6357 (Pubitemid 15220838)
161. Hatters DM, MacPhee CE, Lawrence LJ, Sawyer WH, Howlett GJ. Human apolipoprotein C-II forms twisted amyloid ribbons and closed loops. Biochemistry 2000; 39: 8276-8283
162. Rocken C, Tautenhahn J, Buhling F, Sachwitz D, Vockler S, Goette A, et al. Prevalence and pathology of amyloid in atherosclerotic arteries. Arterioscler Thromb Vasc Biol 2006; 26: 676-677
163. Howlett GJ, Moore KJ. Untangling the role of amyloid in atherosclerosis. Curr Opin Lipidol 2006; 17: 541-547
164. Medeiros LA, Khan T, El Khoury JB, Pham CL, Hatters DM, Howlett GJ. Fibrillar amyloid protein present in atheroma activates CD36 signal transduction. J Biol Chem 2004; 279: 10643-10648 (Pubitemid 38372676)
165. O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 1998; 98: 519-527 (Pubitemid 28371249)
166. Stewart CR, Wilson LM, Zhang Q, Chi LLPham, Waddington LJ, Staples MK, et al. Oxidized cholesterol metabolites found in human atherosclerotic lesions promote apolipoprotein C-II amyloid fibril formation. Biochemistry 2007; 46: 5552-5561 (Pubitemid 46717277)
167. Bruns GA, Karathanasis SK, Breslow JL. Human apolipoprotein A-I- C-III gene complex is located on chromosome 11. Arteriosclerosis 1984; 4: 97-102. (Pubitemid 14152887)
168. Onat A, Hergenc G, Sansoy V, Fobker M, Ceyhan K, Toprak S, et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 2003; 168: 81-89 (Pubitemid 36555814)
169. Wu AL, Windmueller HG. Relative contributions by liver and intestine to individual plasma apolipoproteins in the rat. J Biol Chem 1979; 254: 7316-7322
170. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990; 249: 790-793 (Pubitemid 20259117)
171. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995; 15: 963-971
172. Kypreos KE, Morani P, Van Dijk KW, Havekes LM, Zannis VI. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice. Biochemistry 2001; 40: 6027-6035
173. Aalto-Setala K, Weinstock PH, Bisgaier CL, Wu L, Smith JD, Breslow JL. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J Lipid Res 1996; 37: 1802-1811 (Pubitemid 26275391)
174. de Silva HV, Lauer SJ, Wang J, Simonet WS, Weisgraber KH, Mahley RW, et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 1994; 269: 2324-2335 (Pubitemid 24035450)
175. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006; 114: 681-687 (Pubitemid 44252310)
176. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 2006; 113: 691-700. (Pubitemid 43754333)
177. Kawakami A, Aikawa M, Nitta N, Yoshida M, Libby P, Sacks FM. Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C α-mediated nuclear factor-κB activation. Arterioscler Thromb Vasc Biol 2007; 27: 219-225 (Pubitemid 46360402)
178. Chan DC, Chen MM, Ooi EMM, Watts GF. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int J Clin Pract 2008; 62: 674-676
179. Kypreos KE. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertri-glyceridemia. Biochemistry 2008; 47: 10491-10502
180. Weisgraber KH. Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994; 45: 249-302.
181. Libeu CP, Lund-Katz S, Phillips MC, Wehrli S, Hernaiz MJ, Capila I, et al. New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E. J Biol Chem 2001; 276: 39138-39144 (Pubitemid 37371284)
182. Weisgraber KH, Rall SC Jr, Mahley RW, Milne RW, Marcel YL, Sparrow JT. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J Biol Chem 1986; 261: 2068-2076 (Pubitemid 17205129)
183. Chroni A, Nieland TJF, Kypreos KE, Krieger M, Zannis VI. SR-BI mediates cholesterol efflux via Its interactions with lipid-bound ApoE. Structural mutations in SR-BI diminish cholesterol efflux. Biochemistry 2005; 44: 13132-13143
184. Li X, Kan HY, Lavrentiadou S, Krieger M, Zannis V. Reconstituted discoidal ApoE-phospholipid particles are ligands for the scavenger receptor BI. The amino-terminal 1-165 domain of ApoE suffices for receptor binding. J Biol Chem 2002; 277: 21149-21157 (Pubitemid 34952250)
185. Thuahnai ST, Lund-Katz S, Anantharamaiah GM, Williams DL, Phillips MC. A quantitative analysis of apolipoprotein binding to SR-BI: multiple binding sites for lipid-free and lipid-associated apolipoproteins. J Lipid Res 2003; 44: 1132-1142 (Pubitemid 37279631)
186. Zhang SH, Reddick RL, Burkey B, Maeda N. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest 1994; 94: 937-945 (Pubitemid 24286433)
187. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-472
188. Ghiselli G, Schaefer EJ, Gascon P, Brewer HB Jr. Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science 1981; 214: 1239-1241 (Pubitemid 12167328)
189. Schaefer E, Gregg R, Ghiselli G, Forte TM, Ordovas JM, Zech LA, et al. Familial apolipoprotein E deficiency. J Clin Invest 1986; 78: 1206-1219
190. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu ReV Genomics Hum Genet 2000; 1: 507-537
191. Linton MF, Hasty AH, Babaev VR, Fazio S. Hepatic apoE expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. J Clin Invest 1998; 101: 1726-1736 (Pubitemid 28198503)
192. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathway involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999; 40: 1-16.
193. Thuren T, Weisgraber KH, Sisson P, Waite M. Role of apolipoprotein E in hepatic lipase catalysed hydrolysis of phospholipid in high density lipoproteins. Biochemistry 1992; 31: 2332-2338
194. Kinoshita M, Arai H, Fukasawa M, Watanabe T, Tsukamoto K, Hashimoto Y, et al. Apolipoprotein E enhances lipid exchange between lipoproteins mediated by cholesteryl ester transfer protein. J Lipid Res 1993; 34: 261-268 (Pubitemid 23067531)
195. De Pauw M, Vanloo B, Weisgraber K, Rosseneu M. Comparison of lipid-binding and lecithin: cholesterol acyltransferase activation of the amino- and carboxyl-terminal domains of human apolipoprotein E3. Biochemistry 1995; 34: 10953-10966
196. Rosenfeld ME, Butler S, Ord VA, Lipton BA, Dyer CA, Curtiss LK, et al. Abundant expression of apolipoprotein E by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1993; 13: 1382-1389 (Pubitemid 23271141)
197. Huang ZH, Fitzgerald ML, Mazzone T. Distinct cellular loci for the ABCA1-dependent and ABCA1-independent lipid efflux mediated by endogenous apolipoprotein E expression. Arterioscler Thromb Vasc Biol 2006; 26: 157-162 (Pubitemid 43732243)
198. Gelissen IC, Harris M, Rye KA, Quinn C, Brown AJ, Kockx M, et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol 2006; 26: 534-540
199. Jessup W, Gelissen IC, Gaus K, Kritharides L. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol 2006; 17: 247-257 (Pubitemid 43786058)
200. Ranalletta M, Wang N, Han S, Yvan-Charvet L, Welch C, Tall AR. Decreased atherosclerosis in low-density lipoprotein receptor knockout mice transplanted with Abcg1-/- bone marrow. Arterioscler Thromb Vasc Biol 2006; 26: 2308-2315 (Pubitemid 44465727)
201. Zhang WY, Gaynor PM, Kruth HS. Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. J Biol Chem 1996; 271: 28641-28646
202. Bielicki JK, McCall MR, Forte TM. Apolipoprotein A-I promotes cholesterol release and apolipoprotein E recruitment from THP-1 macrophage-like foam cells. J Lipid Res 1999; 40: 85-92.
203. Kockx M, Rye KA, Gaus K, Quinn CM, Wright J, Sloane T, et al. Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux. J Biol Chem 2004; 279: 25966-25977 (Pubitemid 38798738)
204. Yancey PG, Yu H, Linton MF, Fazio S. A pathway-dependent on apoE, ApoAI, and ABCA1 determines formation of buoyant high-density lipoprotein by macrophage foam cells. Arterioscler Thromb Vasc Biol 2007; 27: 1123-1131
205. Riddell DR, Graham A, Owen JS. Apolipoprotein E inhibits platelet aggregation through the L-arginine: nitric oxide pathway. Implications for vascular disease. J Biol Chem 1997; 272: 89-95. (Pubitemid 27021129)
206. Riddell DR, Vinogradov DV, Stannard AK, Chadwick N, Owen JS. Identification and characterisation of LRP8 (apoER2) in human blood platelets. J Lipid Res 1999; 40: 1925-1930.
207. Stannard AK, Riddell DR, Sacre SM, Tagalakis AD, Langer C, Von Eckardstein A, et al. Cell-derived apolipoprotein E (apoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cell. J Biol Chem 2001; 276: 46011-46016 (Pubitemid 37370847)
208. Sacre SM, Stannard AK, Owen JS. Apolipoprotein E isoforms differentially induce nitric oxide production in endothelial cells. FEBS Lett 2003; 540: 181-187 (Pubitemid 36398054)
209. Ishigami M, Swertfeger DK, Hui MS, Granholm NA, Hui DY. Apolipoprotein E inhibition of vascular SMC proliferation but not the inhibition of migration is mediated through activation of inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2000; 20: 1020-1026 (Pubitemid 30207576)
210. Kothapalli D, Fuki I, Ali K, Stewart SA, Zhao L, Yahil R, et al. Antimitogenic effects of HDL and ApoE mediated by Cox-2 dependent IP activation. J Clin Invest 2004; 113: 609-618 (Pubitemid 38542510)
211. Swertfeger DK, Hui DY. Apolipoprotein E receptor binding versus heparan sulfate proteoglycan binding in its regulation of smooth muscle cell migration and proliferation. J Biol Chem 2001; 276: 25043-25048 (Pubitemid 37412981)
212. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14: 55-61. (Pubitemid 26301547)
213. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb Vasc Biol 1994; 14: 605-616 (Pubitemid 24116931)
214. Hayek T, Oiknine J, Brook JG, Aviram M. Role of HDL apolipoprotein E in cellular cholesterol efflux. Studies in apoE knockout transgenic mice. Biochem Biophys Res Commun 1994; 205: 1072-1078
215. Kelly ME, Clay MA, Mistry MJ, Hsieh-Li HM, Harmony JA. Apolipoprotein E inhibition of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell Immunol 1994; 159: 124-139
216. Hui DY, Harmony JAK. Inhibition of calcium accumulation in mitogen-activated lymphocytes: role of membrane-bound plasma lipoproteins. Proc Natl Acad Sci USA 1980; 77: 4764-4768
217. Kirszbaum L, Bozas S, Walker I. SP40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulfide bridges. FEBS Lett 1992; 297: 70-76
218. de Silva H, Harmony J, Stuart W, Gil C, Robbins J. Apolipoprotein J: structure and tissue distribution. Biochem Biophys Res Commun 1990; 29: 5380-5389
219. Tobe T, Minoshima S, Yamase S, ChoiMiura NH, Tomita M, Shimizu N. Assignment of a human serum glycoprotein SP40,40 (CLI) to chromosome 8. Cytogenet Cell Genet 1991; 57: 193-195
220. Kirszbaum L, Sharpe J, Murphy B, d'Apice A, Classon B, Hudson P, et al. Molecular cloning and characterization of the novel, human complementassociated protein, SP40,40: a link between the complement and reproductive system. EMBO J 1989; 8: 711-718
221. Aronow BJ, Lund SD, Brown TL, Harmony JA, Witte DP. Apolipoprotein J expression at fluid-tissue interfaces: potential role in barrier cytoprotection. Proc Natl Acad Sci USA 1993; 90: 725-729
222. de Silva H, Stuart W, Duvic C, Wetterau J, Ray W, Ferguson D, et al. A 70 kDa apolipoprotein designated apoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem 1990; 265: 13240-13247 (Pubitemid 20234278)
223. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Wagner AC, Hama S, et al. An oral ApoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25: 1932-1937 (Pubitemid 41243465)
224. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, et al. Potential clinical utility of high-density lipoprotein-mimetic peptides. Curr Opin Lipid 2006; 17: 440-444 (Pubitemid 44079483)
225. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, et al. Effects of increasing hydrophobicity on the physical-chemical and biological properties of class A amphipathic helical peptide. J Lipid Res 2001; 42: 1096-1104 (Pubitemid 32645791)
226. Duan J, Dahlback B, Villoutreix BO. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. FEBS Lett 2001; 499: 127-132 (Pubitemid 32539335)
227. Zhang XY, Dong X, Zheng L, Luo GH, Liu YH, Ekstrom U, et al. Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem 2003; 105: 67-72. (Pubitemid 36313933)
228. Faber K, Axler O, Dahlback B, Nielsen LB. Characterization of apoM in normal and genetically modified mice. J Lipid Res 2004; 45: 1272-1278 (Pubitemid 38802630)
229. Dahlback B, Nielsen LB. Apolipoprotein M - a novel player in high-density lipoprotein metabolism and atherosclerosis. Current Opin Lipidol 2006; 17: 291-295 (Pubitemid 43786064)
230. Xu N, Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem 1999; 274: 31286-31290
231. Xu N, Nilsson-Ehle P, Ahren B. Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects. J Nutr Biochem 2004; 15: 579-582 (Pubitemid 39470211)
232. Richter S, Shih DQ, Pearson ER, Wolfrum C, Fajans SS, Hattersley AT, et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003; 52: 2989-2995 (Pubitemid 37466870)
233. Leiter LA, Fitchett D. Optimal care of cardiovascular disease and type 2 diabetes patients: shared responsibilities between the cardiologist and diabetologist. Atheroscler Suppl 2006; 7: 37-42.
234. Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlback B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006; 47(8): 1833-1843 (Pubitemid 44222834)
235. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for preb-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005; 11: 418-422 (Pubitemid 40562332)
236. Glomset JA. The plasma lecithins: cholesterol acyltransferase reaction. J Lipid Res 1968; 9: 155-167
237. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000; 1529: 245-256
238. Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin: cholesterol acyltransferase. Diabetologia 2007; 50: 643-653 (Pubitemid 46215509)
239. Sakai N, Vaisman BL, Koch CA, Hoyt RF Jr, Meyn SM, Talley GD, et al. Targeted disruption of the mouse lecithin: cholesterol acyltransferase (LCAT) gene: generation of a new animal model for human LCAT deficiency. J Biol Chem 1997; 272: 7506-7510 (Pubitemid 27166465)
240. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997; 38: 191-205. (Pubitemid 27118033)
241. Ji Y, Wang N, Ramakrishnan R, Sehayek E, Huszar D, Breslow JL, et al. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem 1999; 274: 33398-33402 (Pubitemid 129511644)
242. Wang N, Arai T, Ji Y, Rinninger F, Tall AR. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. J Biol Chem 1998; 273: 32920-32926 (Pubitemid 28557684)
243. Hoeg JM, Santamarina-Fojo S, Berard AM, Cornhill JF, Herderick EE, Feldman SH, et al. Overexpression of lecithin: cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA 1996; 93: 11448-11453 (Pubitemid 26347141)
244. Vaisman BL, Klein HG, Rouis M, Berard AM, Kindt MR, Talley GD, et al. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem 1995; 270: 12269-12275
245. Mehlum A, Muri M, Hagve TA, Solberg LA, Prydz H. Mice overexpressing human lecithin:cholesterol acyltransferase are not protected against diet-induced atherosclerosis. APMIS 1997; 105: 861-868 (Pubitemid 27483633)
246. Berard AM, Foger B, Remaley A, Vaisman BL, Talley G, Paigen B, et al. High plasma HDL concentration associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med 1997; 3: 744-749 (Pubitemid 27298717)
247. Foger B, Chase M, Amar MJ, Vaisman BL, Shamburek RD, Paigen B, et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 1999; 274: 36912-36920 (Pubitemid 30016758)
248. Hovingh GK, Hutten BA, Holleboom AG, Petersen W, Rol P, Stalenhoef A, et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation 2005; 112: 879-884 (Pubitemid 41170075)
249. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996; 33: 498-507. (Pubitemid 26159866)
250. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001; 21: 542-547 (Pubitemid 32323386)
251. Mackness MI, Hallam SD, Peard T, Warner S, Walker CH. The separation of sheep and human serum "A"-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp Biochem Physiol B 1985; 82: 675-677
252. Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ, et al. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 1998; 213: 149-157 (Pubitemid 28284734)
253. Fuhrman B, Volkova N, Aviram M. Paraoxonase 1 (PON1) is present in postprandial chylomicrons. Atherosclerosis 2005; 180: 55-61. (Pubitemid 40501352)
254. Deakin S, Moren X, James RW. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 2005; 179: 17-25. (Pubitemid 40249782)
255. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999; 19: 2214-2225 (Pubitemid 29422255)
256. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997; 99: 2005-2019 (Pubitemid 27175949)
257. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004; 11: 412-419 (Pubitemid 38568944)
258. Marchegiani F, Marra M, Olivieri F, Cardelli M, James RW, Boemi M, et al. Paraoxonase 1: Genetics and activities during aging. Rejuven Res 2008; 11: 113-127
259. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005; 44: 6371-6382 (Pubitemid 40570731)
260. Teiber JF, Draganov DI, La Du BN. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem Pharmacol 2003; 66: 887-896
261. Jakubowski H, Ambrosius WT, Pratt JH. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett 2001; 491: 35-39 (Pubitemid 32171996)
262. Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, et al. Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. Biochem Biophys Res Commun 2002; 290: 391-396 (Pubitemid 34694511)
263. Draganov DL, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schiedebergs Arch Pharmacol 2004; 369: 78-88.
264. Leviev I, Deakin S, James RW. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res 2001; 42: 528-535 (Pubitemid 32366995)
265. van Himbergen TM, van Tits LJH, Roest M, Stalenhoef AFH. The story of PO N1: how an organophosphatehydrolysing enzyme is becoming a player in cardiovascular medicine. Netherlands Journal of Medicine 2006; 64: 34-38 (Pubitemid 43285584)
266. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-1138
267. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-154
268. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590 (Pubitemid 28198486)
269. Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006; 281: 7657-7665 (Pubitemid 43847536)
270. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-287 (Pubitemid 28335041)
271. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003; 54: 371-392
272. La Du BN. Is paraoxonase-3 another HDL-associated protein protective against atherosclerosis? Arterioscler Thromb Vasc Biol 2001; 21: 467-468
273. Draganov DL, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000; 275: 33435-33442
274. Draganov DL, Sass KM, Watson CE, Bisgaier CL, Reddy ST, Teiber JF, et al. The N-terminal sequences of human paraoxonase-1 (PON1) and paraoxonase-3 (PON3) are responsible for their different translocation and secretion. Circulation 2002; 106(II): 123.
275. Draganov DL. Human PON3, Effects Beyond the HDL. Clues From Human PON3 Transgenic Mice. Circ Res 2007; 100: 1104-1105
276. Tselepis AD, Chapman MJ. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002; 3: 57-68.
277. Tew DC, Southan C, Rice SQJ, Lawrence GMP, Li H, Boyd HF, et al. Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler Thromb Vasc Biol 1996; 16: 591-599 (Pubitemid 126451259)
278. Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J Biol Chem 1987; 262: 4223-4230 (Pubitemid 17102640)
279. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem 1991; 266: 11095-11103 (Pubitemid 21906916)
280. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 2003; 14: 421-430 (Pubitemid 37297296)
281. Mitsios JV, Vini MP, Stengel D, Ninio E, Tselepis AD. Human platelets secrete the plasma type of platelet-activating factor acetylhydrolase primarily associated with microparticles. Arterioscler Thromb Vasc Biol 2006; 26: 1907-1913 (Pubitemid 44305349)
282. Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M, et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 1999; 261: 511-514 (Pubitemid 29392507)
283. Ninio E. Phospholipid mediators in the vessel wall: involvement in atherosclerosis. Curr Opin Clin Nutr Metab Care 2005; 8: 123-131 (Pubitemid 40289471)
284. Lee C, Sigari F, Segrado T, Horkko S, Hama S, Subbaiah PV, et al. All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase. Arterioscler Thromb Vasc Biol 1999; 19: 1437-1446
285. Macphee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338: 479-487 (Pubitemid 129512274)
286. Tselepis AD, Dentan C, Karabina S-AP, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995; 15: 1764-1773
287. Anderson JL. Lipoprotein-associated phospholipase A2: An independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 2008; 101: 23F-33F.
288. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21: 481-488 (Pubitemid 32323377)
289. Theilmeier G, De Geest B, Van Veldhoven PP, Stengel D, Michiels C, Lox M, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J 2000; 14: 2032-2039 (Pubitemid 30747258)
290. Quark R, De Geest B, Stengel D, Mertens A, Lox M, Theilmeier G, et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103: 2495-2500 (Pubitemid 32493377)
291. Noto H, Hara M, Karasawa K, Iso ON, Satoh H, Togo M, et al. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23: 829-835 (Pubitemid 36566173)
292. Turunen P, Puhakka H, Rutanen J, Hiltunen MO, Heikura T, Gruchala M, et al. Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Atherosclerosis 2005; 179: 27-33. (Pubitemid 40253581)
293. Arakawa H, Qian JY, Baatar D, Karasawa K, Asada Y, Sasaguri Y, et al. Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits. Circulation 2005; 111: 3302-3309 (Pubitemid 40875004)
294. Tsimihodimos V, Karabina S-AP, Tambaki AP, Bairaktari E, Miltiadous G, Goudevenos JA, et al. Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 2002; 43: 256-263 (Pubitemid 34184012)
295. Okamura K, Miura S-I, Zhang B, Uehara Y, Matsuo K, Kumagai K, et al. Ratio of LDL- to HDL-associated platelet-activating factor acetylhydrolase may be a marker of inflammation in patients with paroxysmal atrial fibrillation. Circ J 2007; 71: 214-219 (Pubitemid 46182695)
296. Ansquer JC, Foucher C, Aubonnet P, Le Malicot K. Fibrates and microvascular complications in diabetes - insight from the FIELD study. Curr Pharm Des 2009; 15(5): 537-552
297. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins - clinical evidence. Curr Pharm Des 2009; 15(5): 479-489
298. Despres JP. Pleiotropic effects of rimonabant: clinical implications. Curr Pharm Des 2009; 15(5): 553-570